RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 91 filers reported holding RHYTHM PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $266,000 | -74.0% | 23,100 | -55.7% | 0.00% | -100.0% |
| Q2 2021 | $1,022,000 | -1.9% | 52,200 | +6.5% | 0.00% | 0.0% |
| Q1 2021 | $1,042,000 | +250.8% | 49,000 | +390.0% | 0.00% | – |
| Q4 2020 | $297,000 | -93.0% | 10,000 | -94.9% | 0.00% | -100.0% |
| Q3 2020 | $4,269,000 | -18.9% | 197,000 | -16.5% | 0.00% | -20.0% |
| Q2 2020 | $5,261,000 | +265.1% | 235,900 | +149.1% | 0.01% | +400.0% |
| Q1 2020 | $1,441,000 | +37.5% | 94,700 | +107.5% | 0.00% | 0.0% |
| Q4 2019 | $1,048,000 | +353.7% | 45,647 | +326.6% | 0.00% | – |
| Q3 2019 | $231,000 | – | 10,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |